Compare MODG & COGT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MODG | COGT |
|---|---|---|
| Founded | 1982 | 2014 |
| Country | United States | United States |
| Employees | 30000 | N/A |
| Industry | Recreational Games/Products/Toys | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 6.5B |
| IPO Year | 1992 | 2018 |
| Metric | MODG | COGT |
|---|---|---|
| Price | $11.54 | $39.97 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 7 | 13 |
| Target Price | $11.36 | ★ $28.08 |
| AVG Volume (30 Days) | ★ 3.6M | 3.1M |
| Earning Date | 11-06-2025 | 11-03-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $4,061,200,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $0.75 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $5.42 | $3.72 |
| 52 Week High | $13.00 | $43.73 |
| Indicator | MODG | COGT |
|---|---|---|
| Relative Strength Index (RSI) | 54.84 | 66.33 |
| Support Level | $11.33 | $37.86 |
| Resistance Level | $12.15 | $43.73 |
| Average True Range (ATR) | 0.53 | 2.14 |
| MACD | -0.10 | -0.60 |
| Stochastic Oscillator | 28.15 | 37.33 |
Topgolf Callaway Brands Corp is a modern golf and active lifestyle company that provides world-class golf entertainment experiences, designs and manufactures premium golf equipment, and sells golf and active lifestyle apparel and other accessories through brands such as, Topgolf, Callaway Golf, Odyssey, TravisMathew, Jack Wolfskin, OGIO and Toptracer. The company's reportable segments are; Topgolf, Golf Equipment and Active Lifestyle. Majority of the revenue is generated from its Topgolf segment which is predominantly comprised of service revenues and expenses from the company operated Topgolf venues, Toptracer ball-flight tracking technology, and WGT digital golf game. Geographically, majority of the revenue for the company is derived from United States.
Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling.